Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Health Minister Calls for Structural Change in Pharma Industry
Health Minister Yasuhisa Shiozaki has expressed his intention to urge the pharmaceutical industry to make a structural transformation to boost its drug discovery capabilities. Mr Shiozaki made the call at a morning press conference on December 9, where he expounded…
To read the full story
Related Article
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
- Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
- The Sooner the Better, Suga Says on Drug Pricing Revamp
December 12, 2016
- Industry’s “No” to Disclosure of Manufacturing Costs Draws Fire from Chuikyo Reps
December 12, 2016
- (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
- Shiozaki Will Bring Chuikyo’s Views to 4-Way Confab, No Paper Planned: Official
December 12, 2016
- (Update) Pharma Trade Groups Express Strong Opposition to Annual Price Revisions: Chuikyo
December 12, 2016
- Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
December 9, 2016
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…